Funding for this research was provided by:
Instituto de Salud Carlos III (PS09/01882, CA08/00141, CM10/00321 and CM09/00038)
Ministerio de Ciencia e Innovación (BES2008-008053)
Red Temática de Investigación Cooperativa en Cancer (RD06/0020/0031 and RD06/0020/0005)
Red de Biobancos Hospitalarios (RD09/0076/00021)
Text and Data Mining valid from 2019-03-16
Received: 3 February 2019
Accepted: 6 March 2019
First Online: 16 March 2019
Compliance with ethical standards
: This study was approved by institutional ethical committee. The written informed consent from all patients included in both studies was obtained according to the Declaration of Helsinki. The study was performed in accordance with the ethical principles of the Declaration of Helsinki and in compliance with institutional or national laws.
: Adrían Alegre has served on advisory boards for Janssen, Celgene, Amgen, and Takeda and received research support from Janssen, Celgene, and Amgen. Javier de la Rubia has received a speaker honorarium from Abbvie, AMGEN, Celgene, Janssen, and Takeda. The other authors, Margarita Blanes, José Ignacio Lorenzo, Paz Ribas, Ana Jiménez, José David González, Ma. José Cejalvo and Carlos Solano, declare they have no conflict of interest.